Abstract Number: 0579 • ACR Convergence 2023
Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes
Background/Purpose: Ischemic stroke is 2-3 times more common in patients with SLE as compared to the general population, and genetic susceptibility in the STAT4 and…Abstract Number: 0596 • ACR Convergence 2023
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis. In…Abstract Number: 0740 • ACR Convergence 2023
Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease
Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators…Abstract Number: 0888 • ACR Convergence 2023
Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. Type 1…Abstract Number: 0908 • ACR Convergence 2023
Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function
Background/Purpose: SLE primarily afflicts women and many SLE patients develop nephritis, a serious complication of lupus. Identification of biomarkers and the pathogenic mechanisms underlying LN…Abstract Number: 0929 • ACR Convergence 2023
Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms
Background/Purpose: SOCS1 (suppressor of cytokine signaling 1) is a suppressor molecule of the JAK/STAT pathway and has been reported to be involved in the pathogenesis…Abstract Number: 1223 • ACR Convergence 2023
Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous multisystemic autoimmune disorder that can cause life-threatening complications. There is a paucity of data on the utility…Abstract Number: 1353 • ACR Convergence 2023
Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study
Background/Purpose: Due to its multisystemic involvement, systemic lupus erythematosus (SLE) can have a significant impact on patients' quality of life (QoL). Sexual (dis)function is a…Abstract Number: 1451 • ACR Convergence 2023
Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease associated with a high degree of variability at onset, which may make SLE diagnosis challenging, with…Abstract Number: 1468 • ACR Convergence 2023
Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have higher risks of developing cardiovascular disease (CVD). Traditional risk factors do not adequately capture the risk of…Abstract Number: 1485 • ACR Convergence 2023
Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that increases the risk of severe clinical outcomes and mortality. However, the association between SLE…Abstract Number: 1502 • ACR Convergence 2023
Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…Abstract Number: 1599 • ACR Convergence 2023
Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus
Background/Purpose: Ultraviolet light (UV) is a known trigger of cutaneous lupus erythematosus (CLE) flares in systemic lupus erythematosus (SLE) patients, yet cell populations and mechanisms…Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…Abstract Number: 2030 • ACR Convergence 2023
Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History
Background/Purpose: Trauma exposures are associated with SLE onset and disease activity; perceived stress is also associated with greater SLE disease activity and worse patient-reported outcomes.…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 150
- Next Page »